KRYS

Krystal Biotech, Inc. (NASDAQ: KRYS), a leader in redosable gene therapies, today announced record-breaking financial results for the fourth quarter…

Executive summary Krystal Biotech has successfully transitioned into a commercial-stage biotechnology powerhouse following the landmark regulatory approval and rapid market…